Your Health, We Care
Regorafenib is the first small-molecule multi-targeted kinase inhibitor to be reported to prolong survival in patients with metastatic colorectal cancer who are resistant to standard therapy
Regorafenib is approved for third-line treatment in patients with metastatic colorectal cancer (mCRC), third-line treatment for patients with gastrointestinal stromal tumors (GIST) and second-line treatment for patients with hepatocellular carcinoma (HCC).
